Acurx Pharmaceuticals Inc (ACXP) Actualités

Form S-8 - Securities to be offered to employees in employee benefit plans

Form POS AM - Post-Effective amendments for registration statement

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. Announces Closing of $1.1 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y., March 10, 2025 STATEN...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering

Acurx Pharmaceuticals, Inc. Announces $1.1 Million Registered Direct Offering PR Newswire STATEN ISLAND, N.Y., March 7, 2025 STATEN ISLAND, N.Y...

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics

Acurx Announces Publication of Nonclinical In Vivo Data Differentiating Ibezapolstat's Gut Microbiome Effects from Other Anti-CDI Antibiotics PR...

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business...

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the...

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors PR Newswire STATEN ISLAND, N.Y., Feb. 19, 2025 STATEN ISLAND...

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR...